SHL Telemedicine Ltd American Depositary Shares (SHLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SHL Telemedicine Ltd American Depositary Shares (SHLT) has a cash flow conversion efficiency ratio of -0.002x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-173.00K) by net assets ($70.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SHLT net asset quality score to measure how much of total assets are equity-financed.
SHL Telemedicine Ltd American Depositary Shares - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how SHL Telemedicine Ltd American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of SHL Telemedicine Ltd American Depositary to evaluate the quality of earnings relative to operating cash generation.
SHL Telemedicine Ltd American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SHL Telemedicine Ltd American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JCH Systems Inc
KQ:033320
|
0.126x |
|
New Advanced Electronics Technologies Co Ltd
TWO:3465
|
-0.107x |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
-0.012x |
|
Rossmax International Ltd
TWO:4121
|
0.044x |
|
Euro Yatirim Holding AS
IS:EUHOL
|
-0.480x |
|
Genus Paper & Boards Limited
NSE:GENUSPAPER
|
0.034x |
|
Wellbiotec Co. Ltd.
KO:010600
|
-0.033x |
|
Helixmith Co. Ltd
KQ:084990
|
-0.013x |
Annual Cash Flow Conversion Efficiency for SHL Telemedicine Ltd American Depositary Shares (2002–2024)
The table below shows the annual cash flow conversion efficiency of SHL Telemedicine Ltd American Depositary Shares from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see SHL Telemedicine Ltd American Depositary market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.25 Million | $-372.00K | -0.009x | +51.56% |
| 2023-12-31 | $76.46 Million | $-1.50 Million | -0.020x | -1489.07% |
| 2022-12-31 | $59.29 Million | $-73.00K | -0.001x | -140.44% |
| 2021-12-31 | $60.76 Million | $185.00K | 0.003x | -97.54% |
| 2020-12-31 | $37.88 Million | $4.68 Million | 0.124x | -60.42% |
| 2019-12-31 | $34.74 Million | $10.85 Million | 0.312x | -7.74% |
| 2018-12-31 | $37.68 Million | $12.76 Million | 0.338x | -16.52% |
| 2017-12-31 | $29.21 Million | $11.84 Million | 0.405x | +2351.00% |
| 2016-12-31 | $23.82 Million | $-429.00K | -0.018x | -119.28% |
| 2015-12-31 | $42.60 Million | $3.98 Million | 0.093x | +284.04% |
| 2014-12-31 | $61.40 Million | $-3.12 Million | -0.051x | -224.28% |
| 2013-12-31 | $68.91 Million | $2.81 Million | 0.041x | +53.22% |
| 2012-12-31 | $60.99 Million | $1.63 Million | 0.027x | +150.66% |
| 2011-12-31 | $66.56 Million | $-3.50 Million | -0.053x | -230.69% |
| 2010-12-31 | $74.70 Million | $3.01 Million | 0.040x | -50.01% |
| 2009-12-31 | $65.30 Million | $5.26 Million | 0.081x | +163.02% |
| 2008-12-31 | $59.07 Million | $-7.55 Million | -0.128x | -329.31% |
| 2007-12-31 | $60.50 Million | $-1.80 Million | -0.030x | -149.30% |
| 2006-12-31 | $29.81 Million | $1.80 Million | 0.060x | +1284.09% |
| 2005-12-31 | $40.78 Million | $-208.00K | -0.005x | -131.86% |
| 2004-12-31 | $81.52 Million | $1.30 Million | 0.016x | +117.32% |
| 2003-12-31 | $87.56 Million | $645.00K | 0.007x | -69.38% |
| 2002-12-31 | $92.06 Million | $2.21 Million | 0.024x | -- |
About SHL Telemedicine Ltd American Depositary Shares
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company als… Read more